Strive, Inc. Terminates Semler Scientific Convertible Notes and Amends Series A Preferred Stock Certificate (SATA) – 8-K Filing Summary
Strive, Inc. filed an 8-K detailing significant amendments to its Variable Rate Series A Perpetual Preferred Stock, primarily increasing dividend payment frequency from quarterly to monthly, effective June 15, 2026. The amendments also specify dividend rate adjustment mechanisms, redemption and repurchase rights for fundamental changes, and voting rights in case of dividend non-payment. These changes are expected to interest income-focused investors and could impact the valuation of the company's preferred and common shares.
The Cooper Companies stock (US2166481027): Drops 0.80% to $59.47
The Cooper Companies stock (COO) dropped 0.80% to $59.47 on May 13, 2026, marking a 27.4% year-to-date decline. Despite the recent dip, the company, specializing in vision care and surgical devices, maintains strong fundamentals and net margins, outperforming some competitors in the healthcare sector. Investors are watching its performance in the growing US healthcare market.
CooperCompanies stock (US21664P1039): Global leader in vision and women's health products
CooperCompanies (Nasdaq: COO) is a global leader in medical technology, specializing in vision care through CooperVision and women's health products via CooperSurgical. The company's core business model focuses on innovation in contact lenses and fertility solutions, with significant revenue driven by daily disposables, toric lenses, and products for IVF procedures. CooperCompanies maintains a strong competitive position by addressing growing demands in vision correction and reproductive health, particularly in North America, Europe, and Asia-Pacific.
Envista Holdings Corporation Common Stock (NY: NVST
This compilation provides recent news and financial updates for Envista Holdings Corporation (NYSE:NVST). It features headlines covering Q1 2026 earnings results, analyst insights, product launches, and broader healthcare industry analysis. The articles highlight Envista's financial performance, market reactions, and related stock movements.
Number of shareholders of The Cooper Companies, Inc. – NASDAQ:COO
The article focuses on the number of shareholders for The Cooper Companies, Inc. (NASDAQ: COO). It provides a snapshot of the stock's market status and indicates that data regarding shareholder numbers is available for different periods, along with value and percentage changes. The information is sourced from financial data providers like ICE Data Services and FactSet.
CooperCompanies stock (US21664P1039): Earnings and growth outlook for US investors
CooperCompanies has released its latest quarterly financial results, showing continued revenue growth and strong margin performance in its eye care and women's health sectors. The company's focus on innovation, geographical expansion, and operational efficiency supports future earnings growth, according to management. Despite structural growth in its healthcare subsectors, investors should consider potential risks like pricing pressure and regulatory scrutiny.
CooperCompanies stock (US21664P1039): Medical device and women's health focus draws investor interest
CooperCompanies, a medical device and women's health specialist, is gaining investor interest due to solid quarterly results and a growth strategy. The company operates two main segments: CooperVision for contact lenses and CooperSurgical for women's health, fertility, and reproductive medicine. This diversified approach and focus on innovation position it well for long-term healthcare trends, although it is subject to typical medical technology sector risks.
Cooper Companies stock hits 52-week low at 59.99 USD By Investing.com
Cooper Companies Inc. stock has dropped to a 52-week low of $59.99, marking a 26.97% decrease over the past year. Despite this downturn, technical indicators suggest the stock may be oversold and undervalued according to InvestingPro analysis, with analysts setting price targets between $69 and $103. The company recently met Q1 fiscal 2026 revenue expectations, surpassed EPS estimates, and raised its full-year guidance, leading to increased price targets from Needham and Barclays.
COO Price History for Cooper Companies Stock
This Barchart.com page provides the price history for Cooper Companies (COO) stock, including current trading data, historical daily prices, and corporate actions. It details 52-week key points like highs, lows, and Fibonacci levels, along with information on how many times the stock has reached new highs and lows over various periods. The article also explains the tools and features available to Barchart members for accessing and analyzing historical market data.
COO Stock Price Prediction 2025-2026 | The Cooper Companies, Inc Forecast
24/7 Wall St. predicts a "BUY" rating for The Cooper Companies, Inc (COO) with a 12-month target price of $82.46, suggesting a 37.44% upside from its current price of $60.00. The forecast includes optimistic and conservative scenarios, projecting COO could reach $92.45 or $73.92 respectively. Analyst sentiment also largely favors a "Buy" with 11 out of 18 analysts recommending it.
Cooper-Standard Holdings Inc. demonstrates strong potential to continuously drive sustainable value creation thanks to its solid business foundation and clear strategic path.
Cooper-Standard Holdings Inc. is positioned for continuous sustainable value creation due to its strong business foundation and strategic direction. The company is actively focusing on achieving high-quality profit growth and improving profit margins through operational optimizations. This strategy aims to solidify its long-term development and enable effective responses to market challenges and growth opportunities.
CooperCompanies Adds Paul Keel to Board of Directors
CooperCompanies announced the appointment of Paul Keel as an independent director to its board, effective July 1, 2026. Keel, with his extensive background as CEO in medical technology and industrial sectors, will also join the Audit Committee, aiming to enhance the company's strategic execution and global operational capabilities. This move is expected to support CooperCompanies' goal of sustained long-term value creation for its stakeholders.
QDEL Stock Down as Q1 Earnings Miss Estimates, Revenues Down Y/Y
QuidelOrtho Corporation (QDEL) reported first-quarter 2026 adjusted loss per share of 4 cents, missing the Zacks Consensus Estimate, despite revenues of $619.8 million surpassing expectations. The company experienced a year-over-year decline in revenues and significant contractions in gross and operating margins, primarily due to weak respiratory testing, Point of Care, and Donor Screening businesses. QDEL maintains its 2026 revenue outlook but lowered its adjusted EPS guidance, with financial concerns including operating cash outflow and elevated debt levels.
CooperCompanies Adds Paul Keel to Board of Directors
CooperCompanies announced the appointment of Paul Keel as an independent director to its board, effective July 1, 2026. Keel, with his extensive CEO experience in medical technology and industrial sectors, will also join the Audit Committee. This move aims to strengthen CooperCompanies' strategic execution and global operational capabilities, supporting long-term value creation.
Sales fell 3%, but Solventum still sees 2026 EPS near top of range
Solventum (NYSE: SOLV) reported Q1 2026 results with net sales of $2.007 billion (a 3.0% reported decrease but 2.1% organic increase) and adjusted diluted EPS of $1.48 (up 10.6%). The company affirmed its full-year 2026 guidance, expecting organic sales growth of 2.0%–3.0% and adjusted EPS toward the high end of $6.40–$6.60, despite negative operating and free cash flow in Q1 due to separation activities and seasonality.
Assessing Cooper Companies (COO) Valuation After Prolonged Share Price Weakness
Cooper Companies (COO) has experienced significant share price weakness, with a 23% decline over the past year. Despite this, Simply Wall St's analysis suggests the stock is currently undervalued by 31.5%, with a fair value estimated at $91.07, driven by expectations of growth from resolving manufacturing constraints for its MyDAY contact lens. However, the current P/E ratio is higher than both its fair ratio and the industry average, indicating a potentially high valuation despite the undervaluation narrative.
CooperCompanies Appoints Paul Keel to its Board of Directors
CooperCompanies (Nasdaq: COO) has announced the appointment of Paul Keel to its Board of Directors as an independent director, effective July 1, 2026. Mr. Keel, who currently serves as President and CEO of Envista Holdings Corporation, will also join the Audit Committee. His extensive experience as a CEO in the medical device sector and in leading global operations is expected to be a significant asset to CooperCompanies.
Press Release: CooperCompanies Appoints Paul Keel to Its Board of Directors
CooperCompanies announced the appointment of Paul Keel, former CEO of Beacon Building Products and current CEO of Pentair, to its Board of Directors. Keel brings extensive experience in publicly traded companies, including leadership roles at 3M and GE. His addition is expected to enhance the board's expertise as CooperCompanies continues to grow.
CooperCompanies appoints Paul Keel to board of directors By Investing.com
CooperCompanies announced the appointment of Paul Keel as an independent director to its Board, effective July 1, 2026. Keel, currently the President and CEO of Envista Holdings Corporation, will also join the company's Audit Committee. This news comes as CooperCompanies recently exceeded Q1 fiscal 2026 earnings expectations and saw analysts raise price targets.
Envista CEO Paul Keel joins CooperCompanies board, audit panel
CooperCompanies announced the appointment of Paul Keel, CEO of Envista Holdings, as an independent director to its Board, effective July 1, 2026. Keel will also join the Audit Committee, bringing extensive experience in medical devices and global operations from his leadership roles at Envista, Smiths Group, and 3M. This appointment is expected to enhance CooperCompanies' strategic execution and long-term value creation.
CooperCompanies Appoints Paul Keel as Independent Director and to the Audit Committee, Effective July 1, 2026
CooperCompanies announced the appointment of Paul Keel as an independent director and to its Audit Committee, effective July 1, 2026. Mr. Keel currently serves as President and CEO of Envista Holdings Corporation and previously held leadership roles at Smiths Group plc and 3M. He brings extensive experience in industrial and medical technology to the board.
BTSG Stock Gains on Q1 Earnings & Revenue Beat, 2026 Outlook Raised
BrightSpring Health Services, Inc. (BTSG) reported strong first-quarter 2026 results, beating analyst estimates for both adjusted earnings per share and revenue. The company saw significant growth across its Pharmacy Solutions and Provider Services segments, leading to a substantial increase in gross profit and operating income. Consequently, BrightSpring has raised its full-year 2026 revenue and adjusted EBITDA guidance.
DexCom Stock Up on Q1 Earnings & Revenues Beat, Margins Rise
DexCom (DXCM) reported strong first-quarter 2026 results, exceeding analyst expectations for both earnings per share and revenues. The company's growth was fueled by robust global demand for its continuous glucose monitoring systems, expanding access, and new product launches, especially internationally. DexCom also increased its profitability outlook for fiscal 2026, driven by operational discipline and continued innovation in its CGM portfolio.
Inside Boston Scientific's $15 billion offer for Alameda's largest employer
Boston Scientific has made a $15 billion offer to acquire Penumbra, Alameda's largest employer. The deal comes less than three months after a Boston Scientific executive first approached Penumbra's co-founders about a potential partnership, highlighting a swift negotiation process. This acquisition is poised to significantly impact the Bay Area's biotech and healthcare sectors.
UBS Group AG Sells 899,580 Shares of The Cooper Companies, Inc. $COO
UBS Group AG significantly reduced its stake in The Cooper Companies, Inc. by selling 899,580 shares in the fourth quarter, decreasing its total holdings to 1,760,530 shares valued at approximately $144.3 million. The Cooper Companies, a medical device firm, recently exceeded Q1 EPS expectations and provided Q2 2026 guidance, maintaining a "Moderate Buy" consensus rating from analysts.
CooperCompanies Announces Release Date for Second Quarter 2026
CooperCompanies (NYSE: COO) announced that it will release its second-quarter 2026 financial results after the market closes on Thursday, June 6, 2026. A conference call for investors will be held at 5:00 PM ET on the same day. Further details for accessing the call and webcast will be provided.
CooperCompanies sets June 4 earnings release, 5 p.m. ET call
CooperCompanies (Nasdaq: COO) announced it will report Q2 2026 financial results on Thursday, June 4, 2026, at 4:15 PM ET, with a conference call following at 5:00 PM ET. The call will discuss results and corporate developments, and can be accessed via dial-in or webcast. This announcement continues the company's regular communication cadence regarding earnings.
Vanguard Group Inc. Sells 425,898 Shares of The Cooper Companies, Inc. $COO
Vanguard Group Inc. has reduced its stake in The Cooper Companies, Inc. ($COO) by 1.8%, selling 425,898 shares, but still holds 23,548,923 shares valued at approximately $1.93 billion. This comes as Cooper Companies reported strong Q1 earnings, beating estimates with $1.10 EPS and $1.02 billion in revenue, and analysts project a "Moderate Buy" rating with a consensus price target of $90.79. The stock is currently trading near its 12-month low, with a market cap of about $11.97 billion.
The Cooper Companies Stock (US21664P1039): Q1 2026 Earnings Set for Release Today
The Cooper Companies (US21664P1039) is poised to release its first-quarter 2026 financial results today, April 30. Investors will be scrutinizing the performance of its contact lenses (CooperVision) and women's health (CooperSurgical) segments for insights into growth, margins, and supply chain resilience. The company operates globally, with a strong presence in the U.S., and is known for its research-driven product development and strategic acquisitions in specialty healthcare.
Cooper Companies stock hits 52-week low at 61.76 USD By Investing.com
Cooper Companies Inc. (COO) stock has fallen to a new 52-week low of $61.76, representing a 23% year-to-date decline, despite recent positive financial news. InvestingPro data indicates the stock is oversold, and its Fair Value analysis suggests it is currently undervalued. The company recently surpassed Q1 fiscal 2026 earnings expectations and raised its full-year guidance, leading analysts like Needham and Barclays to increase their price targets.
8-Day Sell-Off Sends Cooper Companies Stock Down -12%
Cooper Companies (COO) has experienced an 8-day losing streak, with its stock falling 12% and its market cap decreasing by $1.7 billion to $12 billion. Trefis assesses the stock as "Fairly Priced" with moderate operating performance and financial condition, suggesting a mix of opportunity and trap. The article includes historical stock performance data for COO against the S&P 500 and points to the potential use of predictive signals for managing stock-specific drawdowns.
8-Day Sell-Off Sends Cooper Companies Stock Down -12%
Cooper Companies (COO) experienced an 8-day losing streak, resulting in a 12% stock price decline and a $1.7 billion reduction in market cap. Despite this drop, Trefis rates COO stock as "Fairly Priced" due to a moderate operating performance and financial condition. The article also provides historical performance data and details on other S&P 500 constituents' gain/loss streaks and key financial metrics for Cooper Companies.
Cooper Companies Stock 8-Day Losing Spree: Stock Falls 12%
Cooper Companies (NYSE: COO) stock has experienced an 8-day losing streak, resulting in a 12% decline. This information is provided by Trefis, a financial data and analysis platform. The article title highlights the recent downturn in the company's stock performance.
The Cooper Companies, Inc. (NASDAQ:COO) Receives Average Rating of "Moderate Buy" from Brokerages
Seventeen analysts have given The Cooper Companies, Inc. (NASDAQ:COO) an average rating of "Moderate Buy," with an average one-year price target of $90.79. The company recently reported Q1 earnings of $1.10 EPS, beating estimates, and revenue of $1.02 billion, up 6.2% year-over-year. Despite positive earnings, the stock opened down 1.9% at $63.09, near its 1-year low, and institutional investors have recently adjusted their holdings.
Cooper Companies stock hits 52-week low at 61.76 USD
Cooper Companies (COO) recently hit a 52-week low of $61.76, marking a 23% year-to-date decline, although InvestingPro data suggests the stock is undervalued and in oversold territory, with management aggressively buying back shares. Despite this downturn, the company reported strong Q1 fiscal 2026 earnings, surpassing expectations and raising full-year guidance, leading analysts like Needham and Barclays to increase their price targets. These positive financial and strategic developments indicate potential for recovery despite current market pressures.
Cooper Companies Stock Plummets 9.9% With 7-Day Losing Streak
Cooper Companies (NYSE: COO) stock has experienced a significant downturn, plummeting 9.9% and extending its losing streak to seven consecutive days. This decline indicates a challenging period for the company's market performance.
Cooper Companies Stock 7-Day Losing Spree: Stock Falls -9.9%
Cooper Companies (COO) has experienced a 7-day losing streak, with its stock falling 9.9% and market cap decreasing by $1.4 billion to $12 billion. Despite its moderate operating performance, the stock is considered unattractive due to its high valuation. The article also provides a historical analysis of COO's performance compared to the S&P 500 and highlights the importance of predictive signals to manage stock-specific drawdowns.
Cooper Companies Stock 7-Day Losing Spree: Stock Falls -9.9%
Cooper Companies (COO) has experienced a 7-day losing streak, with cumulative losses of 9.9%, leading to a market cap reduction of $1.4 billion. Despite a moderate operating performance and financial condition, the stock is considered "Unattractive" due to its High valuation. The article also provides historical performance data against the S&P 500 and points to Trefis's High Quality Portfolio for predictive signals to manage stock-specific risks.
The Cooper Companies Projects Significant Earnings Growth for Q2 2026
The Cooper Companies (COO) is expected to report significant earnings growth for fiscal Q2 2026, with analysts projecting $1.10 per share, a 14.6% increase year-over-year. The company has a strong track record of exceeding Wall Street expectations and reported robust Q1 FY2026 results with a 6% revenue increase and a 20% adjusted EPS rise. Despite a 22% stock decline over the past year, analysts maintain a "Moderate Buy" rating with an average price target of $90.60.
Robert Half selected by Forbes as one of America's Best Employers for Company Culture 2026
Robert Half has been recognized by Forbes as one of America's Best Employers for Company Culture 2026, based on a comprehensive evaluation of workplace policies and an independent survey of 217,000 workers. The company was lauded for its commitment to integrity, inclusion, innovation, and a people-first approach that fosters employee growth and well-being. This award, along with previous recognitions from Fortune and Newsweek, underscores Robert Half's dedication to creating a positive and engaging work environment.
Cooper Companies Earnings Preview: What to Expect
Cooper Companies (COO) is set to announce its fiscal 2026 Q2 earnings, with analysts projecting a 14.6% increase in EPS to $1.10. The company's strong Q1 performance, driven by growth in both its CooperVision and CooperSurgical divisions, led management to raise its full-year guidance. Despite underperforming the broader market, analysts have a "Moderate Buy" rating on COO with a significant potential upside of over 40%.
Tangible book value per share of Cooper Companies, Inc. – MUN:CP60
This page provides financial information specifically the tangible book value per share for Cooper Companies, Inc. (MUN:CP60). It appears to be a financial data portal from TradingView, offering an overview of the company's financials on the Munich Stock Exchange.
Cooper Companies Earnings Preview: What to Expect
Cooper Companies (COO) is set to announce its fiscal Q2 2026 earnings, with analysts expecting a 14.6% increase in profit to $1.10 per share. This follows a strong Q1 FY2026 performance where revenue grew 6% year-over-year and adjusted EPS rose 20%. Despite underperforming market indices over the past year, Wall Street analysts maintain a "Moderate Buy" rating with a significant potential upside.
Here's Why The Cooper Companies (COO) is a Strong Growth Stock
The Cooper Companies (COO) is identified as a strong growth stock by Zacks Equity Research. The article likely details the underlying reasons for this assessment, potentially touching upon financial performance, market position, or future prospects. Investors are offered a free report from Zacks for further analysis.
Browning West pushes Cooper Cos. board to appoint its directors
Browning West is urging Cooper Companies' board to appoint its directors. This indicates a push for board representation and potential strategic shifts within the company.
Is Cooper Companies (COO) Now Attractive After Recent Share Price Weakness?
Cooper Companies (COO) has experienced recent share price weakness, with declines over the past week, month, year-to-date, and 1-year period. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 17.5% compared to its intrinsic value of approximately $84.16 per share. However, its Price-to-Earnings (P/E) ratio of 33.76x is above the industry average, indicating it may be overvalued based on earnings multiples.
The Cooper Companies, Inc. $COO Shares Sold by Boston Trust Walden Corp
Boston Trust Walden Corp significantly reduced its stake in The Cooper Companies (NASDAQ:COO) by 17.2% in the fourth quarter, selling 257,481 shares and now holding 1,237,479 shares valued at approximately $101.4 million. Despite the sell-off, Cooper Companies exceeded quarterly EPS estimates with $1.10 versus $1.03 consensus and reported revenues of $1.02 billion, a 6.2% year-over-year increase. Analyst sentiment remains guardedly positive, with a "Moderate Buy" consensus and a price target of $90.79, although ratings vary from Strong Buy to Sell.
Asset Management One Co. Ltd. Grows Stock Holdings in The Cooper Companies, Inc. $COO
Asset Management One Co. Ltd. increased its holdings in The Cooper Companies, Inc. (NASDAQ:COO) by 34.2% in the fourth quarter of the previous year, now owning 109,034 shares valued at $8.96 million. Other institutions like Capital World Investors, State Street Corp, and Wellington Management Group also significantly raised their stakes, bringing the total institutional ownership to about 24.39%. Cooper Companies recently exceeded Q1 EPS estimates and provided Q2 2026 EPS guidance, maintaining a "Moderate Buy" consensus rating among analysts.
Zacks Industry Outlook Highlights Cardinal, Becton and The Cooper
The Zacks Medical - Dental Supplies industry is poised for continued growth in 2026 due to innovation, an aging population, and increased healthcare needs. The article highlights Cardinal Health (CAH), Becton, Dickinson and Co. (BDX), and The Cooper Companies (COO) as key players benefiting from favorable market trends. It discusses their individual performance expectations for fiscal year 2026, including forecasted revenues and EPS, while also addressing potential challenges like competitive pressures and tariffs.
Director at Cooper Companies (NYSE: COO) gains 832 vested shares
Cooper Companies director Walter M. Rosebrough Jr. acquired 832 vested shares of common stock, which originated from a grant of 832 Restricted Stock Units (RSUs) on January 3, 2026, that vested on April 1, 2026. He now directly holds 832 shares and indirectly holds 10,000 shares through a revocable trust. The required Form 4 was filed late due to an administrative oversight.
